Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 4, 2006

View Archived Issues

Dengue virus vaccine research progresses

Clinical evaluation anticipated for ABT-737

Novel Smac mimetic may have potential as anticancer therapy

F3-targeted nanoparticle formulation may be useful to image and treat brain tumors

Promising results of PRTX-100 in a murine model of arthritis

Pfizer's novel EP1 receptor antagonist may be useful to treat incontinence

Spider toxins provide clues for understanding mechanisms of inflammatory pain

Delay to phase III results for glufosfamide

Dyax and CSIRO collaborate to discover and develop cancer antibody therapeutics

Durect and Nycomed sign agreement for Posidur

FDA Advisory Committee to discuss planned RESUS trial of Hemopure

Medivir and Jiangsu Hengrui Medicine extend COPD collaboration

Iclaprim demonstrates noninferiority to linezolid in cSSSI

Single-dose regimen of Synvisc effective in osteoarthritis

ReNeuron and CellSeed collaborate on liver cell culture systems

TPO mimetic LGD-4665 enters phase I testing

Pfizer offers pipeline progress report

Actavis to acquire Abrika

Anesiva grants Lumen access to data on prevention of saphenous vein graft disease

Sirtris obtains rights to sirtuin technology from MIT

VistaGen and Sanwa renew embryonic stem cell partnership

Pfizer plans maraviroc multinational expanded access program

Lentigen receives SBIR funding to develop new therapy for CLL

RVX-208 increases ApoA-I by 150% in first 24 hours

Ranbaxy patents novel muscarinic receptor antagonists

Novel therapeutic agents for neurological disorders reported in recent patent literature

Recent patents impart new anticancer compounds

Pfizer stops all torcetrapib clinical trials

Champix launched in U.K.

Daiichi Sankyo acquires U.K. rights for repaglinide, plans rebranding

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...